Cotadutide vs Efinopegdutide

Head-to-head comparison of Cotadutide (MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist) and Efinopegdutide (Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyCotadutideEfinopegdutide
CategoryWeight ManagementWeight Management
Full NameMEDI0382, long-acting GLP-1 and glucagon receptor dual agonistEfinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist
Molecular Weight~4,700 DaN/A
Half-LifeApproximately 24 hoursApproximately 1 week
Amino Acids37N/A
Typical Dose0.3-3 mg daily in clinical studiesTrial-dependent; weekly SC dosing
RouteSubcutaneousSubcutaneous
Purity≥98%≥98%
Studies Count1814
Research StatusClinicalClinical

Cotadutide Benefits

  • body-weight reduction
  • improved insulin sensitivity
  • reduced hepatic fat
  • appetite suppression

Efinopegdutide Benefits

  • reduced body weight
  • improved insulin sensitivity
  • reduced liver fat
  • greater satiety

Cotadutide Dosing

Once-daily SC in trials|Start low and titrate based on tolerance|Monitor GI adverse effects

Efinopegdutide Dosing

once-weekly subcutaneous injection|dose escalation during lead-in|maintenance dosing in trials

Cotadutide Side Effects

  • nausea
  • vomiting
  • diarrhea

Efinopegdutide Side Effects

  • nausea
  • decreased appetite
  • fatigue

Research Overview

Cotadutide

Phase 2 studies reported dose-dependent weight loss and favorable changes in glycemic and liver-related markers. It is one of the most cited synthetic dual-agonist peptides for obesity research.

Efinopegdutide

Human trials have shown meaningful weight loss and improvements in hepatic steatosis biomarkers. It remains a research compound with ongoing development in metabolic disease.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

Cotadutide stacks with:

dietary-calorie-restrictionexercise-program

Efinopegdutide stacks with:

metforminorlistat
GLP-1glucagon-coagonistdual-agonistobesity-researchglp1glucagonobesitynash